ViroPharma Inc. (VPHM) reported a fourth-quarter GAAP net loss of $3.9 million or $0.06 per share compared to a GAAP net income of $53.1 million or $0.65 per share in the fourth quarter of 2011.
However, on an adjusted basis the company posted a profit of $7.1 million, or $0.10 per share.
Meanwhile, net sales fell to $106.49 million for the fourth quarter, from $145.57 million in the same three months of 2011.
Analysts polled by Thomson Reuters expected the company to report earnings of $0.03 per share on revenues of $103.06 million for the quarter. Analysts' estimates typically exclude special items.
For the year 2013, ViroPharma expects Worldwide net product sales to be in the range $450 million to $475 million, reflective of updated expectations for Vancocin. Net U.S. Cinryze sales are expected to be $390 million to $400 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.